Peptide Straight Talk
Issue #1
Evidence framed as of September 15, 2026 · Revised September 20, 2026
Educational / research framing only · Not medical advice
Peptide Straight Talk
Research-desk still-life · Peptide Straight Talk Issue #1.
Editor’s note
This is Issue #1 of Peptide Straight Talk — traceable peptide research notes for smart beginners: not forum consensus, not vendor protocol sheets, and not a clinic script. We open with basics, then go deep on one compound.
Byline: Peptide Straight Talk editorial desk.
Cutoff note: Claims and registry fields in this issue are framed as of September 15, 2026. Revised September 20, 2026 for clarity; the evidence cutoff itself was not silently refreshed.
Basics: peptides, evidence labels, and what the FDA is doing
Not medical advice. This issue is educational research intelligence for beginners — not a protocol, not a shopping list, and not permission to use any unapproved substance.
What is a peptide?
A peptide is a short chain of amino acids (the building blocks of proteins). Many approved medicines and many investigational research compounds are peptides or peptide-related. The word peptide alone does not tell you whether something is FDA-approved, safe, effective, or legal to compound.
Online catalogs sometimes use “peptide,” “research chemical,” “compounded,” and “trial drug” as if they were the same object. Peptide Straight Talk keeps those labels separate so you can see what is actually being claimed.
How we label claims (two axes — design ≠ source)
When you see a claim here, ask two separate questions:
What kind of study? Example: randomized controlled trial (RCT) = a design (random assignment).
What source are we reading? Examples: JOURNAL-PRIMARY (full journal primary-results article), conference materials (CONF), company / sponsor release (SPONSOR), trial registry record (REG), regulatory / authority statement (REG-AUTH), community / vendor claim (COMM).
A ClinicalTrials.gov status of COMPLETED is a registry field only. It is not the same as sponsor materials, and it is not the same as a full journal primary-results article. Keep three objects separate:
Registry status (REG) — what the trial record says (including COMPLETED).
Sponsor / conference materials (SPONSOR / CONF) — what a company release or meeting put in public.
JOURNAL-PRIMARY — an original journal study report; peer-review status is recorded separately.
RCT = design. A sponsor press release or conference talk can describe an RCT without being a JOURNAL-PRIMARY article. Peer-review status is stated separately when a row needs it (for example: design: RCT · source: JOURNAL-PRIMARY · peer-reviewed: yes).
When a journal paper appears later, it is an additional source. Earlier SPONSOR or CONF materials keep their labels.
Free beginner glossary (plain language first): https://www.peptidestraighttalk.com/p/free-beginner-glossary (see Beginner reference at the end of this issue).
Current U.S. regulatory stance (plain English)
The FDA (U.S. Food and Drug Administration) is the principal U.S. regulator for drugs and biologics. For peptide research notes, keep three ideas separate:
Approval — Has FDA found a product safe and effective for a labeled use? Most “research peptides” discussed online are not FDA-approved drugs for the uses people talk about in casual threads.
Compounding — Federal compounding rules (including section 503A) are conditional and narrower than casual threads imply. Many research peptides meet none of the bulk pathways FDA describes.
Agency status pages — FDA also publishes positions on unapproved glucagon-like peptide-1 (GLP-1)-related drugs and compounding limits. Those pages are REG-AUTH sources: what the agency currently says — not a personal recommendation.
Detailed 503A sequence (licensed pharmacist / eligible physician, identified patient, USP/NF monograph → approved-drug component → 503A Bulks List, plus nominations vs final list): see the free beginner glossary — https://www.peptidestraighttalk.com/p/free-beginner-glossary.
What FDA is doing in this lane (as of this issue’s framing): policing products outside lawful pathways; stating when a named investigational molecule cannot be used in compounding under federal law; and separating nominations, advisory votes, and final list actions so they are not collapsed into “FDA approved.”
We start every deep dive with that regulatory floor — then we walk the evidence stack for one molecule.
Study-design / model legend (not Axis B):
Tag: RCT
Meaning (short): Randomized controlled trial design (random assignment). Pair with a separate source tag — RCT alone does not mean a full journal primary-results article
Tag: ANIMAL
Meaning (short): Preclinical animal model evidence
Source-type legend (Axis B) — publication / provenance types only:
Tag: JOURNAL-PRIMARY
Meaning (short): Full journal primary-results article; a source/publication tag, not a study-design tag. State peer-review status separately when needed
Tag: CONF
Meaning (short): Conference presentation / abstract / symposium slides — public, but not a full journal primary report
Tag: SPONSOR
Meaning (short): Company topline / investor press release — news, not a full journal primary report
Tag: REG
Meaning (short): Trial registry record — registration/status fields are not the same as posted registry results or a full journal primary report
Tag: REG-AUTH
Meaning (short): Regulatory / authoritative position statement (e.g., FDA)
Tag: COMM
Meaning (short): Community / catalog / internet claim — not elevated to study evidence
Tag: REV
Meaning (short): Secondary review / synthesis
Upcoming-event status (not a source type): WATCH-NEXT = agenda / upcoming presentation only — not results today. Used on calendar rows; not part of the source-type legend above.
If a headline upgrades a press release into “Phase 3 proven,” we don’t. A later journal article is an additional source; earlier releases retain their original classification.
This issue’s only in-depth compound: retatrutide.
Research-desk detail · Peptide Straight Talk Issue #1.
Feature: Retatrutide, TRIUMPH-1, and why COMPLETED still does not mean published results
Takeaway (read this first)
In short: Retatrutide (LY3437943) is an investigational triple agonist — not FDA-approved, and FDA states it cannot be compounded under federal law. TRIUMPH-1 is an RCT by design whose ClinicalTrials.gov status is COMPLETED, but as of September 15, 2026 the public TRIUMPH-1 result sources are still SPONSOR and CONF — not a JOURNAL-PRIMARY article. COMPLETED ≠ published results (see above). Phase 2 obesity still has a JOURNAL-PRIMARY report (Jastreboff NEJM 2023; peer-reviewed: yes). Tables and timeline below keep the full depth.
Identity first (before the hype)
Retatrutide is the International Nonproprietary Name for an investigational triple agonist (one medicine that activates three hormone pathways) at the GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. The development code is LY3437943.
Catalog aliases — “GLP-3-R,” “Reta,” various “3R” shorthand codes — are COMM labels. They do not, by themselves, prove that a research-chem vial is pharmaceutical trial material. We start every deep dive by pinning Identity first: if the molecule isn’t clear, the rest of the claim map is hard to trust.
What FDA already locked in (REG-AUTH)
Before trial status, sit with the regulatory floor. On FDA’s page FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (checked 2026-09-15), the agency states that retatrutide cannot be used in compounding under federal law, that it is not a component of an FDA-approved drug, and that it has not been found safe and effective for any condition.
That is a REG-AUTH box. It does not depend on whether ClinicalTrials.gov says RECRUITING or COMPLETED. It does not melt because a sponsor issues an investor release. Threads that treat “trial drug exists” as “compounding / gray-market vials are fine” skip this floor.
Trial supply ≠ community / vendor vials. That distinction is intentional, not pedantry.
How we walk the evidence (why the order matters)
For each molecule we keep a simple spine so readers can follow along without a paid product:
Identity — International Nonproprietary Name (INN) / code vs catalog alias
Regulatory snapshot (REG-AUTH) — what the agency already said
Claim / evidence map — each claim with a design tag and a source tag
What this does NOT establish — explicit ceilings
Internet claim vs evidence — COMM rows live here, never beside design or source rows (RCT / CONF / SPONSOR) as if they were peers
For retatrutide, the load-bearing rows:
Discovery / early development (Coskun et al., 2022). Coskun and colleagues described LY3437943 as a novel triple glucagon / GIP / GLP-1 receptor agonist from discovery through early clinical proof-of-concept, including preclinical weight and glycemic findings and Phase 1 work supporting a weekly pharmacokinetic concept (Cell Metabolism, 2022;34(9):1234-1247.e9; doi:10.1016/j.cmet.2022.07.013 · PMID:35985340). Tiering: ANIMAL plus early human — useful for mechanism and development history, not a substitute for later randomized obesity outcomes.
Phase 2 obesity — JOURNAL-PRIMARY article (Jastreboff et al., 2023). For retatrutide, this is the Current JOURNAL-PRIMARY obesity efficacy report—as of September 15, 2026. It reports weekly subcutaneous dose arms in a randomized, double-blind, placebo-controlled obesity program (Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial, N Engl J Med. 2023;389(6):514–526; doi:10.1056/NEJMoa2301972 · PMID:37366315). Tags: design: RCT · source: JOURNAL-PRIMARY · peer-reviewed: yes.
From the published abstract (same paper): 338 adults were enrolled. Least-squares mean percent body-weight change at 24 weeks (primary): about −7.2% (1 mg), −12.9% (combined 4 mg), −17.3% (combined 8 mg), and −17.5% (12 mg) vs −1.6% with placebo. At 48 weeks: about −8.7%, −17.1%, −22.8%, and −24.2% vs −2.1% placebo. Gastrointestinal adverse events were the most common, dose-related, and mostly mild to moderate. The abstract also reports dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter. When someone asks “what full randomized primary-results tables for obesity can I open and cite end-to-end?”, this is still that row. (This does not imply it is the only later randomized peer-reviewed retatrutide publication — TRANSCEND-T2D-1 exists for type 2 diabetes.)
That does not mean Phase 3 randomized human data are absent from public view. Phase 3 has been announced as topline results (SPONSOR) and presented (CONF). Those layers are real — and they are still SPONSOR/CONF ≠ JOURNAL-PRIMARY for TRIUMPH-1 obesity. If a TRIUMPH-1 journal paper later appears, it becomes an additional source; May/June SPONSOR/CONF rows keep their labels.
Phase 3 TRIUMPH-1 on ClinicalTrials.gov. NCT05929066 — official title: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-1); sponsor Eli Lilly; design described as randomized, double-blind, placebo-controlled. Registry fields accessed 2026-09-15 list status COMPLETED, with primary completion 2026-04-06 and study completion 2026-04-30. Tags for this registry row: Study design: RCT · Source: REG.
Applied here: TRIUMPH-1 is an RCT by design; its registry source stays REG (COMPLETED ≠ published results). As of September 15, 2026, TRIUMPH-1 result sources remain SPONSOR / CONF, not JOURNAL-PRIMARY. If a TRIUMPH-1 journal paper appears later, it becomes an additional row; May/June materials keep their labels.
What changed since the May topline
Freshness timeline as of the September 15, 2026 evidence framing — source types labeled.
Figure G2 — Freshness timeline (as of 2026-09-15).
May 21 SPONSOR → June 6 (CONF congress vs SPONSOR investor, separate sources) → July 23 SPONSOR → Sept 30 WATCH-NEXT agenda only. Dates/tags only; no efficacy bars.
Figure note: Public TRIUMPH calendar from May through a September 30 agenda item — tags only, no efficacy bars. The freshness table below carries the full responsible-say rows.
When: May 21, 2026
What: Lilly investor topline · TRIUMPH-1
Tag: SPONSOR
What you can responsibly say: Sponsor-reported topline in adults with obesity/overweight without diabetes (per release). Doses 4 / 9 / 12 mg; ~80-week primary. Efficacy-estimand means (sponsor definition: an analysis estimating outcomes assuming participants continued treatment without prohibited weight-management treatments): 19.0% (4 mg), 25.9% (9 mg), 28.3% / 70.3 lb (12 mg) vs 2.2% placebo; BMI ≥35 extension to 104 weeks. Treatment-regimen estimand differs (see live-case). Not JOURNAL-PRIMARY.
When: June 6, 2026
What: ADA 86th Sessions · TRIUMPH-1 talk (Jastreboff) + session metadata + Lilly HCP congress page
Tag: CONF
What you can responsibly say: Public Phase 3 TRIUMPH-1 at ADA (New Orleans). ADA newsroom/locator = session metadata only (marketing title). Lilly HCP page: design: RCT · source: CONF. Nested knee osteoarthritis (OA) / Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and obstructive sleep apnea (OSA) / apnea–hypopnea index (AHI) baskets as presented; CONF ≠ JOURNAL-PRIMARY. Same-day TRANSCEND-T2D-1 Lancet = different trial.
When: June 6, 2026
What: Lilly ADA-day investor release (HTML + PDF)
Tag: SPONSOR
What you can responsibly say: Same-day investor companion to ADA. Weight-loss frame + nested OA/OSA toplines as sponsor-reported. Separate from CONF above — SPONSOR ≠ JOURNAL-PRIMARY.
When: July 23, 2026
What: Lilly investor topline · TRIUMPH-2 + TRIUMPH-3
Tag: SPONSOR
What you can responsibly say: Sponsor-reported Phase 3 toplines (July 23 release). TRIUMPH-2 (obesity/overweight + type 2 diabetes (T2D)): up to 20.8% / 49.6 lb at 80 weeks (12 mg). Separately, hemoglobin A1C (A1C, a longer-term blood-sugar marker) decreased by 1.6 percentage points at 9 mg and 1.5 percentage points at 12 mg. TRIUMPH-3 (severe obesity + established cardiovascular disease (CVD), with or without type 2 diabetes (T2D)): up to 22.6% / 55.8 lb at 80 weeks (12 mg). Estimand detail: see release. Still SPONSOR; JOURNAL-PRIMARY later if/when full tables publish. BLA Q1 2027 = sponsor plan language, not a regulatory decision.
When: Watch next
What: EASD 2026 agenda (announced 2026-09-15) · Sept 30 TRIUMPH-2 symposium
Tag: WATCH-NEXT
What you can responsibly say: Agenda/programme only. A scheduled presentation alone does not establish results. Re-check after Sept 30 for slides / simultaneous pubs.
May SPONSOR figures remain useful. Stopping at May would be stale; promoting June slides or July toplines to JOURNAL-PRIMARY would be sloppy.
The live case: SPONSOR / CONF ≠ JOURNAL-PRIMARY
On May 21, 2026, Eli Lilly issued an investor news release describing sponsor-reported topline results from TRIUMPH-1 (link in Sources). That row is SPONSOR.
Carefully summarized (still SPONSOR, not JOURNAL-PRIMARY):
All listed retatrutide doses in the topline (4 mg, 9 mg, and 12 mg) met primary and key secondary endpoints for obesity at 80 weeks (per release).
Headline means on the efficacy estimand (sponsor definition above): 19.0% (4 mg), 25.9% (9 mg), 28.3% / 70.3 lb (12 mg) at 80 weeks, vs 2.2% placebo; with a pre-specified BMI ≥35 extension to 104 weeks. On the treatment-regimen estimand (average effect regardless of adherence or prohibited weight-management treatments, per release), 80-week means were −17.6% (4 mg), −23.7% (9 mg), −25.0% (12 mg), and −3.9% placebo.
Safety context in the same release (sponsor-reported): most common adverse events with retatrutide vs placebo included nausea, diarrhea, constipation, and vomiting; discontinuation due to adverse events was 4.1% / 6.9% / 11.3% (4 / 9 / 12 mg) vs 4.9% placebo. Full published safety/efficacy appendices are still not available as a TRIUMPH-1 journal primary report as of the September 15 framing.
Responder-style thresholds and sponsor-characterized cardiometabolic marker language appear in the release — treat as topline framing, not a full published appendix.
Why don’t we upgrade May (or June, or July) to JOURNAL-PRIMARY tomorrow morning? Because SPONSOR is still a company communication and CONF is still a meeting presentation — neither is a full journal primary-results article. Headline verbs change faster than source types. A later journal article is an additional source; earlier rows keep their labels. (Design can already be RCT; that does not change the source.)
So the honest stack, as of 2026-09-15, looks like this:
Figure G1a — Evidence stack map, part A (as of 2026-09-15).
Part A — layers from REG-AUTH through May 21 SPONSOR. COMPLETED ≠ published results; SPONSOR ≠ JOURNAL-PRIMARY. Continues in Figure G1b.
Figure note (part A): Stack from FDA posture through Phase 2 JOURNAL-PRIMARY, TRIUMPH-1 registry COMPLETED, and May 21 SPONSOR topline — no efficacy bars. Continues in Figure G1b; the combined table after G1b carries the full responsible-say rows.
Figure G1b — Evidence stack map, part B (as of 2026-09-15).
Part B — June 6 CONF/SPONSOR through COMM, plus legend/footer. TRANSCEND does not transfer to TRIUMPH-1; SPONSOR/CONF ≠ JOURNAL-PRIMARY. Table below has full responsible-say rows.
Figure note (part B): Continues with June CONF/SPONSOR, July SPONSOR, TRANSCEND as a separate JOURNAL-PRIMARY contrast, EASD WATCH-NEXT agenda, and COMM aliases. The table below carries the full responsible-say rows.
Layer: FDA compounding / approval posture
Label: REG-AUTH
What you can responsibly say: Retatrutide cannot be compounded under federal law; not a component of an FDA-approved drug; not found safe/effective for any condition (FDA page, checked 2026-09-15)
Layer: Phase 2 obesity — full journal primary-results article
Label: design: RCT · source: JOURNAL-PRIMARY · peer-reviewed: yes
What you can responsibly say: Jastreboff NEJM 2023 — current JOURNAL-PRIMARY obesity efficacy report as of September 15, 2026 (N=338; LS means at 24/48 weeks; GI AEs; HR finding per abstract)
Layer: TRIUMPH-1 ClinicalTrials.gov record
Label: design: RCT · source: REG
What you can responsibly say: COMPLETED registry status + design/population/dates — COMPLETED ≠ published results
Layer: Lilly May 21, 2026 TRIUMPH-1 investor release
Label: design: RCT · source: SPONSOR
What you can responsibly say: Topline figures (efficacy + treatment-regimen estimands; AE/discontinuation context) — SPONSOR ≠ JOURNAL-PRIMARY
Layer: ADA June 6, 2026 TRIUMPH-1 symposium + ADA session metadata + Lilly HCP congress TRIUMPH-1 page
Label: design: RCT · source: CONF
What you can responsibly say: Presented Phase 3 TRIUMPH-1 (incl. nested OA/OSA baskets) — CONF ≠ JOURNAL-PRIMARY
Layer: Lilly June 6, 2026 ADA-day investor release (HTML + PDF)
Label: design: RCT · source: SPONSOR
What you can responsibly say: Investor companion topline (incl. nested OA/OSA baskets); not CONF — SPONSOR ≠ JOURNAL-PRIMARY
Layer: Lilly July 23, 2026 TRIUMPH-2 / TRIUMPH-3 investor release
Label: SPONSOR
What you can responsibly say: Additional Phase 3 toplines (A1C and weight kept separate in freshness table); BLA Q1 2027 = sponsor plan language; estimand detail — see release; SPONSOR ≠ JOURNAL-PRIMARY
Layer: TRANSCEND-T2D-1 Lancet (published online June 6, 2026; print June 13, 2026) — different trial
Label: design: RCT · source: JOURNAL-PRIMARY · peer-reviewed: yes
What you can responsibly say: Phase 3 type 2 diabetes (T2D) program arm — contrast only; does not upgrade TRIUMPH-1
Layer: EASD Sept 30, 2026 TRIUMPH-2 symposium (announced Sept 15)
Label: WATCH-NEXT (upcoming-event status)
What you can responsibly say: Agenda only until post-meeting materials / pubs
Layer: Catalog “GLP-3-R / Reta / 3R” vials
Label: COMM
What you can responsibly say: Alias ≠ verified pharmaceutical identity
That is the map: figures show layers and calendar; tables carry the responsible-say rows.
Why headlines “upgrade” and we don’t
Press cycles reward verbs: delivered, cleared, powerful. Registry UIs reward status chips: COMPLETED looks like a finish line. Conference apps reward “just presented.” All are useful signals. None is a substitute for keeping design, source, and calendar separate on the claim map.
If notes jump from “NCT COMPLETED” or “just presented at ADA” → “Phase 3 proven at X%” without a JOURNAL-PRIMARY article in the middle, that is headline compression. Issue #1 makes that compression visible — and leaves the numbers you can responsibly use next to their tags.
Beginner reference
For plain-language definitions of the evidence tags (RCT, JOURNAL-PRIMARY, CONF, SPONSOR, REG, REG-AUTH, WATCH-NEXT, and the rest) and the detailed 503A compounding sequence, start with the free Peptide Straight Talk Beginner Glossary: https://www.peptidestraighttalk.com/p/free-beginner-glossary
What this issue does NOT establish
FDA approval of retatrutide for any condition
Lawful compounding of retatrutide under federal law (FDA states it cannot be used in compounding)
That ClinicalTrials.gov COMPLETED means published results (or that it upgrades a source tag by itself)
That a Lilly investor topline (SPONSOR) or ADA symposium / HCP congress materials (CONF) equal a JOURNAL-PRIMARY article for TRIUMPH-1
That TRANSCEND-T2D-1’s Lancet JOURNAL-PRIMARY article transfers to TRIUMPH-1 obesity
That vendor “GLP-3-R / Reta / 3R” vials equal pharmaceutical trial LY3437943
Human-use protocols, syringe-draw plans, or personal dosing instructions (explicitly out of scope)
Diagnosis, treatment, cure, or prevention of any disease
Sources (access framing 2026-09-15 unless noted)
FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (retatrutide compounding / not a component of an FDA-approved drug).
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-lossCoskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013 · PMID:35985340
Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972 · PMID:37366315
ClinicalTrials.gov NCT05929066 (TRIUMPH-1) — status COMPLETED; primary completion 2026-04-06; study completion 2026-04-30 (registry fields; access date 2026-09-15).
https://clinicaltrials.gov/study/NCT05929066SPONSOR — Eli Lilly investor news release, May 21, 2026: “Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial” (TRIUMPH-1 topline; efficacy / treatment-regimen estimands; AE rates as reported).
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
PDF mirror: https://investor.lilly.com/node/54321/pdfCONF / ADA session metadata — American Diabetes Association newsroom: “Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity,” June 6, 2026 (TRIUMPH-1 talk metadata: Jastreboff, ~2:15–2:35 p.m. CT). Session metadata only; newsroom title is marketing voice.
https://diabetes.org/newsroom/press-releases/breakthrough-studies-demonstrate-effectiveness-first-triple-hormone-therapy
Session locator: https://events.diabetes.org/p/s/results-of-first-phase-3-study-of-retatrutide-a-gip-glp-1-and-glucagon-receptor-agonist-in-patients-with-obesity-triumph-1-5581CONF — Lilly HCP congress materials, June 6, 2026: TRIUMPH-1 ADA Scientific Sessions page — design: RCT · source: CONF (congress presentation materials; nested OA/OSA baskets as presented). Not an investor release.
https://www.lilly.com/hcp/congresses/ada-2026/dv039292-triumph-1SPONSOR — Eli Lilly investor news release, June 6, 2026: “Lilly’s triple agonist, retatrutide, drove substantial improvements…” (ADA-day investor companion; nested OA/OSA basket toplines as sponsor-reported). HTML + PDF.
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-drove-substantial-improvements
https://investor.lilly.com/node/54396/pdfSPONSOR — Eli Lilly investor news release, July 23, 2026: “Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials…” (TRIUMPH-2 / TRIUMPH-3 toplines; BLA plan Q1 2027 per release as sponsor plan language; detailed results deferred to future meetings/journals).
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additionaldesign: RCT · source: JOURNAL-PRIMARY · peer-reviewed: yes — TRANSCEND-T2D-1 Phase 3 in The Lancet (different trial) — published online June 6, 2026; print issue June 13, 2026 (simultaneous with ADA June 6, 2026 per Lilly/ADA). doi:10.1016/S0140-6736(26)00967-0 · PubMed: https://pubmed.ncbi.nlm.nih.gov/42250575/ — does not upgrade TRIUMPH-1.
WATCH-NEXT (upcoming-event status; Axis B provenance: SPONSOR announcement / programme) — Lilly EASD 2026 announcement dated Sept 15, 2026 (PR Newswire); programme lists Wed Sept 30, 2026 8:30–9:30 a.m. CEST TRIUMPH-2 symposium.
https://www.prnewswire.com/news-releases/lilly-to-present-new-data-on-foundayo-retatrutide-and-eloratzp-at-easd-2026-as-it-strives-to-change-the-course-of-cardiometabolic-health-302878341.html
https://www.easd.org/uploads/EASD2026_Final-Programme.pdfFDA — Human Drug Compounding / bulk drug substances used in compounding (503A context: licensed pharmacist or eligible licensed physician; prescription for identified patient; conditional sequence — USP/NF monograph + compounding chapter, else approved-drug component, else 503A Bulks List; list ≠ nominations / interim / evaluated-not-included).
https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding
Disclaimer
Educational and research information only. This newsletter is not medical advice, not a diagnosis, not a prescription, and not a recommendation to use any unapproved substance. It does not provide human-use protocols or syringe-draw instructions. Evidence tags describe source types for research notes; they are not treatment guidance. Retatrutide and related compounds discussed here are framed with FDA regulatory context and published/registry/conference/sponsor sources as cited — not as consumer products or compounding recipes. Always read primary sources yourself. Consult a licensed clinician for personal health decisions.
© 2026 Peptide Straight Talk · Issue #1